Doi Hiroshi, Fujiwara Masayuki, Suzuki Hitomi, Niwa Yasue, Nakayama Masahiro, Shikata Toshiyuki, Odawara Soichi, Takada Yasuhiro, Kimura Takeshi, Kamikonya Norihiko, Hirota Shozo
Department of Radiology, Hyogo College of Medicine, The Hospital of Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Department of Pharmacy, The Hospital of Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Mol Clin Oncol. 2015 Mar;3(2):381-386. doi: 10.3892/mco.2014.479. Epub 2014 Dec 19.
Polaprezinc (PZ), an antiulcer drug, has been reported to have antioxidant properties. The aim of the present study was to assess the feasibility and efficacy of administering PZ for radiation-induced mucositis in head and neck cancer patients. Patients with newly diagnosed head and neck cancer were enrolled in this prospective study. PZ was prepared as an oral rinse. The PZ oral rinse was used four times per day during the course of radiotherapy. Sequential changes in radiation mucositis were assessed during and after radiotherapy according to the Common Terminology Criteria for Adverse Events, version 3.0. Furthermore, a retrospective comparison analysis was performed to assess the efficacy of PZ for radiation-induced mucositis. A total of 32 patients were enrolled in the prospective study of the PZ oral rinse. Radiotherapy was performed up to a total dose of 60-66 Gy using a conventional schedule combined with chemotherapy. Of the 32 patients, 30 (93.8%) reported no complaints due to the PZ oral rinse. In addition, PZ was not associated with severe adverse effects. Among the patients who received PZ, grade 3 mucositis was observed in 29.0% based on the mucosal findings and in 39.3% based on the symptoms. In the patients who did not receive PZ, the incidence of grade 3 mucositis was 40.0% based on the mucosal findings and 60.7% based on the symptoms. Moreover, PZ promoted the recovery from mucositis caused by chemoradiotherapy and was not associated with reduced tumor response to radiotherapy. Therefore, the PZ oral rinse was well tolerated and proved to be efficient for the treatment of radiotherapy-induced oral mucositis.
聚普瑞锌（PZ）是一种抗溃疡药物，据报道具有抗氧化特性。本研究的目的是评估在头颈部癌患者中给予PZ治疗放射性口腔黏膜炎的可行性和疗效。新诊断的头颈部癌患者被纳入这项前瞻性研究。PZ被配制成口腔含漱液。在放疗期间，PZ口腔含漱液每天使用4次。根据不良事件通用术语标准3.0版评估放疗期间及放疗后的放射性口腔黏膜炎的序贯变化。此外，进行了回顾性比较分析以评估PZ对放射性口腔黏膜炎的疗效。共有32例患者被纳入PZ口腔含漱液的前瞻性研究。采用常规方案联合化疗进行放疗，总剂量达60 - 66 Gy。在这32例患者中，30例（93.8%）报告使用PZ口腔含漱液后无不适。此外，PZ未引发严重不良反应。在接受PZ的患者中，根据黏膜表现，3级口腔黏膜炎的发生率为29.0%，根据症状则为39.3%。在未接受PZ的患者中，根据黏膜表现，3级口腔黏膜炎的发生率为40.0%，根据症状则为60.7%。此外，PZ促进了放化疗引起的口腔黏膜炎的恢复，且与放疗的肿瘤反应降低无关。因此，PZ口腔含漱液耐受性良好，被证明对治疗放疗引起的口腔黏膜炎有效。
